Summary Bryostatin 1, a novel antineoplastic agent and protein kinase C (PKC) activator, has been found to induce myalgia (muscle pain) 48 h after administration in clinical trials. This is the dose-limiting toxicity and has restricted the duration of therapy in phase I trials. To investigate the mechanisms and try to increase toleration of the drug, we studied calf muscle metabolism of 14 patients at rest and during exercise and subsequent recovery using 31P magnetic resonance spectroscopy (MRS) before and 4 h, 48 -72 h and 1-2 weeks following bryostatin therapy. In resting muscle there was a significant (P<0.001) increase in the phosphodiester/adenosine 5'-triphosphate (PDE/ATP) ratio 48 h post bryostatin and in patients with myalgia compared with pre-bryostatin control studies. Following exercise, patients with myalgia showed significantly slower phosphocreatine (PCr) and ADP recovery half-time (P <0.05) suggesting impaired mitochondrial (oxidative) energy production, possibly due to a direct effect on the mitochondria or secondary to reduced blood flow. The apparent proton efflux rate following exercise was significantly reduced 4 h after bryostatin (P <0.05), suggesting reduced blood flow. The rate of post-exercise reoxygenation was studied in four patients by near-infrared spectroscopy 4 h post bryostatin. In three of these the rate was reduced, consistent with reduced muscle blood flow. Bryostatin 1 appeared to cause a long-lasting impairment of oxidative metabolism and proton washout from muscle, consistent with a vasoconstrictive action. Thus these studies provide evidence for two mechanisms of the dose-limiting toxicity for bryostatin. Prospective studies on the use of vasodilators to improve the tolerance of the drug should be carried out.
Bryostatin 1 is the prototype of a novel family of potent activators of protein kinase C (PKC) (Berkow and Kraft, 1985) , isolated from the marine invertebrate Bugula neritina (Pettit et al., 1982) . Following the display of potent antineoplastic actions in cell lines and animal models (Hornung et al., 1992) , mainly ascribed to cell signalling modifications, clinical phase I trials exploring potential antineoplastic actions in patients were commenced. Difficulties arose because patients experienced myalgia (generalised muscle pain), characteristically starting 48 h after bryostatin administration. The pain involved all muscle groups, especially calves and thighs, but also including retro-orbital muscles. The pain included both muscle stiffness and tenderness, and could be relieved partly by hot baths and movement. Treatment therefore had to be withdrawn in 17% of patients (Philip et al., 1993) and myalgia remains the dose-limiting toxicity, both for single injections and for chronic administration (Prendiville et al., 1988) . A variety of analgesics, including morphine and steroids, were ineffective in reducing this pain, which was not associated with an elevation of serum creatine kinase or with urine myoglobin excretion, and did not correlate in time with observed increases in circulating cytokine concentrations (Philip et al., 1993) . The mechanisms of the pain remain unknown (Philip et al., 1993) . To try and overcome the dose-limiting toxicity and enable continuous use of this novel agent, a series of magnetic resonance spectroscopy (MRS) studies was carried out.
Muscle pain is perceived following stimulation of muscle pain receptors (nociceptors), and can be a consequence of muscle cell destruction, involvement of intramuscular blood vessels, or defective energy metabolism, as found in painful myopathies (Mills and Edwards, 1983;  Morgan-Hughes, 1987 ). Owing to their carcinogenic nature, other PKC activators such as the phorbol esters have not been investigated in humans. Despite this, the consequences of PKC activation in animal muscle appear to be relatively diverse, resulting in stimulated prostaglandin production, histamine and serotonin release (Naka et al., 1983; Halenda et al., 1985; Mobley and Tai, 1985) , smooth muscle vasoconstriction (Mori et al., 1990) , cardiac depression, coronary vasoconstriction and abnormal energy metabolism in the isolated perfused heart (Watson and Karmazyn, 1991) , and myofibrillar disorganisation in skeletal muscle (Doetschman and Eppenberger, 1984; Moses and Claycomb, 1989) .
The non-invasive technique of 31P MRS has been extensively used in the investigation of skeletal muscle energy metabolism. In particular, it can detect abnormalities of glycogenolytic and oxidative ATP synthesis as well as of net proton efflux from the cell . We therefore carried out a 3'P MRS exercise/recovery study of calf muscle to search for evidence in bryostatin-induced myalgia-of either mitochondrial dysfunction per se, or of abnormal mitochondrial function and net proton efflux secondary to vasoconstriction. To assist in distinguishing these possible abnormalities, in some patients we also studied reoxygenation times after ischaemic exercise in forearm muscle in vivo using near-infrared spectroscopy. Table I . Informed consent was obtained from all subjects and the work performed with ethics committee approval. Treatment consisted of 25 Lg m2 bryostatin by intravenous infusion over 1 h (50 iLg m-2 bryostatin in one patient). This was administered once a week for 3 weeks with no treatment during the 4th week, followed by 3 more treatment weeks (a total of six doses per course of treatment). Thirteen MRS studies were obtained before bryostatin therapy, and early and late post-bryostatin studies were organised to study muscle at 4-6 h (n = 10) usually before the occurrence of myalgia and at 48-72 h (n = 7) when myalgia was present. Each timed group contained no more than one study from each patient. Owing to clinical or technical difficulties two patients were studied at 24 h and three patients 1-2 weeks after bryostatin. Of all the above studies, 11 were obtained in the presence of myalgia: these were also combined as a 'myalgia' group, including single data sets from three patients and two data sets from four patients.
Materials and methods

Magnetic
Subjects were placed in a 90 cm wide-bore 2T superconducting magnet (Oxford Instruments, Oxford, UK) interfaced to a Bruker spectrometer (Bruker, Coventry, UK) with the right calf overlying a 6-cm-diameter surface coil. Data were collected with an 80 ,ls pulse width and a 2 s interpulse delay. Two 64-scan spectra were acquired from the muscle at rest. Patients exercised by performing plantar flexion of the right ankle lifting a weight of 10% lean body mass (obtained from skinfold thickness using standard tables; Durnin and Womersley, 1974) . After 5 min of exercise, the weight was increased by 2% lean body mass every 1.25 min until the patient complained of fatigue or rapid PCr depletion was observed. Thirty-two scan spectra (1.25 min) were collected throughout exercise, and recovery was monitored by collecting four 8-scan spectra, four 16-scan, three 32-scan and two 64-scan spectra (13 min of recovery in total). Signals were detected from inorganic phosphate (Pi), phosphocreatine (PCr), adenosine triphosphate (ATP), phosphomonoesters (PME) and phosphodiesters (PDE), and were processed by exponential multiplication and Fourier transformation. Signal intensities were obtained by using a time domain fitting programme (VARPRO, R. de Beer, Utrecht, Holland), which identifies a specified number of exponentially decaying signals in the free induction decay acquired from the muscle, using prior knowledge of the expected amplitudes, relative positions and widths of the peaks to be For kinetic analysis, data were assigned to the midpoint of the acquisition interval. The decrease in pH and PCr during the acquisition of the last exercise spectrum (which provides part of the data used for calculation of initial PCr recovery and proton efflux) was corrected for by linear extrapolation of pH and PCr/(PCr +Pi) from the midpoints of the last two exercise spectra to the end of the last exercise spectrum.
During exercise, ATP is produced by net hydrolysis of PCr which removes protons, glycogenolysis to lactic acid (which generates 1.5 protons per ATP) and oxidative phosphorylation, which produces a negligible proton load . Over the first exercise interval (i.e. from rest state to the first data point in exercise, 1.5 times the sum of the rates at which protons are consumed by net hydrolysis of PCr and taken up by cellular buffers (over this interval, where pH changes are small, it can be assumed that proton efflux is negligible). Thus the total rate of non-oxidative ATP synthesis is given by
where 6.75 is the pK of phosphoric acid and P is the cytosolic buffer capacity (Kemp et al., 1993a,b) .
The recovery of pH after exercise depends on the proton efflux, and this was quantified by using changes in pH and
[PCr] at the start of recovery to calculate the initial rate of proton efflux in recovery ; this is taken as the sum of the rates at which protons are released by PCr resynthesis and made available from the cellular buffers. The calculation 
Results
31P MRS results
In resting muscle, no differences were observed at 4 h postbryostatin, though PDE/ATP was significantly increased by 100 ± 29% at 48 h and by 87 ± 28% for the whole myalgic group (Table II) . During exercise, there was no significant difference between the groups with respect to the initial rate of ATP synthesis, the duration or the end-exercise state (Table III) .
Results during recovery from exercise are shown in Table  IV pre-bryostatin study (control) (*P <0.05, **P <0.01, ***P <0.001). Each timed group contains no more than one study from each patient. The myalgia group consists ofall the studies obtained in the presence ofmyalgia and includes single data sets from three patients and two data sets from four patients. aFor these three studies mean control pH was 6.99 ± 0.01 and post-bryostatin pH was 7.01 ± 0.01. pH and metabolite ratios obtained at the end ofexercise are shown. The length oftime spent exercising is stated. Results obtained at the beginning ofexercise were used to derive the non-oxidative ATP synthesis rate. Results are shown as overall mean ± s.e.m. for all studies in each category. Student's paired t-test compared values from each individual's post-bryostatin study with their pre-bryostatin study (control) (*P <0.05, ** P <0.01, ***P <0.001). Each timed group contains no more than one study from each patient. The myalgia group consists of all the studies obtained in the presence of myalgia and includes single data sets from three patients and two data sets from four patients. The overall half-times for metabolite recovery are shown. Data obtained immediately following exercise cessation were used to calculate the rate of PCr recovery, proton efflux and calculated mitochondrial capacity (Q,,.,). Results are displayed as mean ± s.e.m. for all studies in each category. Student's paired t-test compared values from each individual's post-bryostatin study with their pre-bryostatin study (control) (*P (0.05, **P (0.01, ***P (0.001). Each timed group contains no more than one study from each patient. The myalgia group consists of all the studies obtained in the presence of myalgia and includes single data sets from three patients and two data sets from four patients.
,D_ calculated initial proton efflux was significantly reduced by 54 ± 17% at 4 h following bryostatin, despite not reaching significance in the myalgic group. Thus differences in recovery after exercise were mainly at 4 h after dosing, whereas changes in PDE/ATP were maximal at 24-48 h and associated with pain. In general, results for those with myalgia were similar to 48-72 h results.
Near infra-red spectroscopy Figure 1 suggests an increase in reoxygenation half-time at 4 h post-bryostatin (when it was higher than control in three out of four patients), which by 48-72 h had returned to its original value. The result did not reach statistical significance, presumably because of the small number of patients in whom this investigation was performed.
Discussion
Muscle pain and energy metabolism In healthy muscle, various noxious stimuli will activate muscle nociceptors, resulting in the perception of muscle pain (Mills and Edwards, 1983) . In pathologically altered muscle, however, substances such as bradykinin, prostaglandin E2 and 5-hydroxytryptamine are released together and interact with other factors such as catecholamines and hypoxia (Kieschke et al., 1988) to lower the mechanical threshold of nociceptors, so that relatively weak stimuli can produce pain (Mense, 1990 (Naka et al., 1983; Halenda et al., 1985; Mobley and Tai, 1985 . There are theoretical reasons why the ADP recovery half-time is a more sensitive index of mitochondrial abnormallties than the PCr recovery half-time . The best quantitative estimate of the size of a functional defect in mitochondrial capacity (either primary or secondary to impaired supply of substrate or oxygen) is the calculated mitochondrial capacity (Q.a) Kemp et al., 1993b ).
We find a reduced PCr resynthesis rate and a reduced Q.
at 4 h post bryostatin and in the myalgic group, associated with slow ADP recovery at 48 h and 1-2 weeks postbryostatin and in the myalgic group (Table IV) . These results are consistent with impaired mitochondrial function following bryostatin administration in both the presence and absence of myalgia. This could in principle be due to either a direct toxic effect on the mitochondria or impaired substrate and oxygen supply as a result of vasoconstriction.
Activators of PKC in smooth muscle bring about contraction following phosphorylation of the myosin light chain kinase (Naka et al., 1983) . Although no work has been published on the effects of bryostatin on smooth muscle, we have recently found that, in the isolated perfused rat heart, bryostatin 1 (like the PKC-activating phorbol esters; Karmazyn et al., 1990) has a dose-dependent coronary vasoconstriction action that is prevented by inhibition of PKC (PF Hickman and K Clarke, unpublished data). Thus, a vaso-constrictive action might be expected in humans following bryostatin, tending to reduce muscle blood flow and resulting in impaired delivery of oxygen and substrate and washout of metabolites, as is seen in patients with peripheral vascular disease (Hands et al., 1986) . In particular, reduced washout from the extracellular space would inhibit net proton efflux, as we found in the 4 h studies (Table IV) . These results are in contrast to those from both genetic and drug-induced mitochondrial myopathies, which display a rapid pH recovery, probably as a result of increased proton efflux (Arnold et al., 1985; Weissman et al., 1992) . These findings are complemented by the near-infrared spectroscopy studies, which suggest a reduction of the rate of reoxygenation following ischaemic exercise for 4 h after bryostatin administration (Figure 1 ).
Direct toxic effects on muscle The phosphodiesters glycerophosphocholine and glycerophosphoethanolamine accumulate in dystrophic muscle and in old age (Edwards et al., 1982) , and this is possibly due to membrane damage. Phorbol esters cause reversible destruction of myofibrils in differentiated muscle cells after 24-48 h of incubation (Doetschman and Eppenberger, 1984) . We detected a significant increase in the PDE/ATP ratio in patients 48 h following bryostatin and when experiencing myalgia (Table II) . If myofibrillar destruction is PKC mediated, then the raised PDE/ATP ratio may reflect a direct toxic effect of bryostatin upon muscle, which may require further evaluation with muscle biopsies.
In conclusion, we have demonstrated two effects of bryostatin treatment on muscle metabolism in vivo during recovery from exercise. First, there is a reduction in mitochondrial function and, secondly, the effective proton efflux is reduced. The simplest hypothesis is a reduction in muscle blood flow subsequent to muscle vasoconstriction, which is consistent with the probable reduced reoxygenation rate we observed after ischaemic exercise, and with the effects of bryostatin and other PKC activators in the perfused heart. Bryostatin may also possess direct toxic effects, suggested by the third observation, namely a rise in PDE/ATP in resting muscle. Bryostatin has detectable effects on muscle cell biochemistry and physiology in vivo. The change most clearly associated with myalgia is the PDE/ATP ratio, which is compatible with pain in resting muscle. The biphasic effects at 4 h and 48 h may reflect in vivo modulation of PKC, with initial transient stimulation followed by prolonged downregulation. Attempts to prevent the initial early change should now be undertaken using vasodilators prospectively, and such a study has been initiated using nifedipine. This study demonstrates the unusual toxicities that may be associated with novel anti-cancer drugs and methods that may be needed to optimise their use.
